Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for prevention of brain metastases in high-risk metastatic breast cancer
2007-005491-14Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer and brain metastases comparing Temozolomide with Control/observation (2 arms). Primary endpoint: 1-year incidence of brain recurrence. Started Jul 2008; status: terminated.
02
Drugs
temozolomide
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2007-005491-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005491-14.